We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Bioprocessing Summit Europe 2020: New Analytical and Formulation Sessions

Bioprocessing Summit Europe 2020: New Analytical and Formulation Sessions content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Cambridge Healthtech Institute (CHI) has announced the return of Bioprocessing Summit Europe, with the addition of approximately 30 new sessions on Analytical and Formulation topics.

Altogether, more than 130 presentations for senior-level scientists and technologists from industry, government and academia will focus on Upstream Processing, Downstream Processing, Cell Therapy CMC and Manufacturing, and Gene Therapy CMC and Manufacturing, as well as innovations in Analytical/Formulation areas.

These sessions aim to provide solutions to the challenges of producing complex biologics while maximizing quality, risk management and cost-efficiency. Experts from such organizations as Novartis, Pfizer, National Institute for Bioprocessing Research and Training (NIBRT), Roche, Merck, Sanofi-Aventis and Bristol-Myers Squibb will share scientific data, insights and case studies on technologies and processes.

“Bioprocessing Summit Europe gives participants a rare opportunity to benchmark with their peers, and benefit from unpublished information that is inaccessible elsewhere,” said Dan Barry, Senior Conference Director, CHI.

The new Analytical and Formulation stream will include two tracks:

  • Analytical Characterization – Optimizing Analytical Development and Characterization, Regulatory Considerations, Novel Protein Formats, and Impurities and Host Cell Proteins (HCPs) 
  • Formulation, Stability & Aggregation – Optimizing Formulation Development, Protein Aggregation, Advances in Stability and Degradation Testing, and Analysis of Impurities, Sub-Visible and Visible Particles

Other conference highlights will include:

  • Plenary Keynotes led by Ralf Schumacher, PhD, Global Head, Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, and Diane Blumenthal, PhD, Head, Technical Development, Spark Therapeutics 
  • Short Courses, Training Seminars, 40 exhibitors, poster sessions and 1-On-1 Networking